Regenerative Medicine, Neurology, Cardiology. Company is developing advanced bioengineering solutions for nerve and blood vessel regeneration to address traumatic and degenerative diseases. The company’s lead […]
Intravenous (IV) drugs leave a huge margin for human error, particularly at the point of administration.
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
The company’s first product is a low-profile “Stent-On-a-Wire” system that reduces the number of steps involved in the stenting procedure.
Register now to attend IN3 West, which takes place March 3-5 at the Venetian Hotel-Resort-Casino in Las Vegas.
“Quitting smoking” is one of the most popular New Year’s resolutions, right up there with “losing weight” and “exercising more.”
Access Pharmaceuticals (OTC: ACCP.OB, “Access”) develops and commercializes products for the treatment and supportive care of cancer patients.
The economy is tough for biotech start-ups, but the CEO of HydraDx is feeling confident.
According to the American Heart Association, heart disease is the number one killer of women over age 25–more than the next five causes of death, or all forms of cancer, combined.
The San Diego-based company aims to reduce the incidence of complications resulting from lumbar spinal surgery, such as nerve damage or degeneration of adjacent discs.
Copyright © 2025 | WordPress Theme by MH Themes